vericiguat


( Last Updated : September 15, 2022)
Generic Name:
vericiguat
Project Status:
Pending
Therapeutic Area:
Heart failure
Manufacturer:
Bayer Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0758-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Bayer requests vericiguat be reimbursed to reduce the risk of cardiovascular death and heart failure (HF) hospitalization, in adults with symptomatic chronic HF and ejection fraction less than 45% who are stabilized after a recent worsening HF event. Vericiguat should be used in combination with other HF therapies. Initiation criteria: • In adult patients with New York Heart Association (NYHA) II to IV chronic HF • Other HF therapies include an angiotensin-converting enzyme inhibitor (ACEi), an angiotensin II receptor antagonist (ARB), or an angiotensin receptor and neprilysin inhibitor (ARNi), a beta-blocker, and if tolerated, a mineralocorticoid receptor antagonist (MRA) • Vericiguat should be initiated under the supervision of a healthcare professional who is experienced in the management of HF.
Submission Type:
Initial
Indications:
Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization, in adults with symptomatic chronic HF and ejection fraction less than 45% who are stabilized after a recent worsening HF event. Vericiguat should be used in combination with other HF therapies.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.